Add to ORKGAlthough most would argue that software patents pose a bigger challenge, the U.S. Supreme Court has recently focused on biomedical patents. Two of the Court\u27s recent decisions scaling back such patents, Mayo v. Prometheus and AMP v. Myriad, have provoked justifiable anxiety for those concerned about biomedical innovation, particularly in the area of personalized medicine. While acknowledging significant limitations in the Court\u27s reasoning in both cases, this Essay sketches a reading that is consistent with the results and innovation-friendly
This Article begins by providing a brief historical retrospective of the development of the patent e...
In Bilski v. Kappos, the U.S. Supreme Court continued to require that patentable subject matter elig...
In Bilski v. Kappos, the U.S. Supreme Court continued to require that patentable subject matter elig...
Although most would argue that software patents pose a bigger challenge, the U.S. Supreme Court has ...
Intellectual property protection in the form of secured patents has played an integral role in the g...
On March 20, 2012, the Supreme Court of the United States unanimously decided the case of Mayo Colla...
The U.S. Supreme Court effectively redefined the scope of patent eligible subject matter when it dec...
Contrary to popular perception, the Supreme Court’s recent decision in Association for Molecular Pat...
The Supreme Court’s 2013 decision in Association for Molecular Pathology v. Myriad Genetics is part ...
35 U.S.C. § 101 allows a patent for “any new and useful process, machine, manufacture, or compositio...
In the last few years in particular, the Court has expanded the zone of exclusion from patent eligib...
The Supreme Court’s decision last Term in Mayo v. Prometheus left considerable uncertainty as to th...
The Supreme Court\u27s recent interest in patentable subject matter has had several, unexpected down...
Recent advances in biotechnology have given researchers the ability to comprehensively examine the g...
This Article explores the Supreme Court’s recent decision in Association for Molecular Pathology v. ...
This Article begins by providing a brief historical retrospective of the development of the patent e...
In Bilski v. Kappos, the U.S. Supreme Court continued to require that patentable subject matter elig...
In Bilski v. Kappos, the U.S. Supreme Court continued to require that patentable subject matter elig...
Although most would argue that software patents pose a bigger challenge, the U.S. Supreme Court has ...
Intellectual property protection in the form of secured patents has played an integral role in the g...
On March 20, 2012, the Supreme Court of the United States unanimously decided the case of Mayo Colla...
The U.S. Supreme Court effectively redefined the scope of patent eligible subject matter when it dec...
Contrary to popular perception, the Supreme Court’s recent decision in Association for Molecular Pat...
The Supreme Court’s 2013 decision in Association for Molecular Pathology v. Myriad Genetics is part ...
35 U.S.C. § 101 allows a patent for “any new and useful process, machine, manufacture, or compositio...
In the last few years in particular, the Court has expanded the zone of exclusion from patent eligib...
The Supreme Court’s decision last Term in Mayo v. Prometheus left considerable uncertainty as to th...
The Supreme Court\u27s recent interest in patentable subject matter has had several, unexpected down...
Recent advances in biotechnology have given researchers the ability to comprehensively examine the g...
This Article explores the Supreme Court’s recent decision in Association for Molecular Pathology v. ...
This Article begins by providing a brief historical retrospective of the development of the patent e...
In Bilski v. Kappos, the U.S. Supreme Court continued to require that patentable subject matter elig...
In Bilski v. Kappos, the U.S. Supreme Court continued to require that patentable subject matter elig...